Market News & Trends
Mateon Provides Update on Global Covid-19 Study
Mateon Therapeutics, Inc. recently announced it has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients, which allows for the continuing…
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
AIM ImmunoTech Inc. recently announced it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen…
Ocuphire Announces Publication of MIRA-1 Phase 2b Results Demonstrating Reduction of Pharmacologically Induced Mydriasis
Ocuphire Pharma recently announced that the results from the MIRA-1 (NCT04024891) Phase 2b clinical trial evaluating the safety and efficacy of Nyxol in the reversal…
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial
Aravive, Inc. recently announced it has dosed its first patient in an open label Phase 1b/2 clinical trial to evaluate the safety, pharmacokinetic, and preliminary…
twoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy & Safety of Two Novel Chronic Kidney Disease Treatment Candidates
twoXAR Pharmaceuticals recently announced two novel leads for the potential treatment of chronic kidney disease (CKD), TXR-1208 and TXR-1210, demonstrated significant efficacy and excellent tolerability…
Codex DNA Releases World’s First Synthetic Genomes for Emerging SARS-CoV-2 Variants
Codex DNA, Inc., recently announced the release of the world’s first full-length synthetic genomes for two emerging variants of the SARS-CoV-2 virus. The new genomes…
Ridgeback Biotherapeutics & Merck Announce Preliminary Findings From Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
Merck and Ridgeback Biotherapeutics recently announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA….
Veru Receives FDA Agreement to Advance VERU-111 Into Phase 3 Study
Veru Inc. recently announced the FDA agreed in an End of Phase 2 meeting, to advance VERU-111 into a Phase 3 registration clinical study based on the clinically meaningful benefits observed with….
Schreiner MediPharm & AARDEX Offer Smart Digital Therapy Management Solution for Clinical Trials
Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has collaborated with AARDEX Group, an expert in digital….
LEXEO Therapeutics Announces License Agreement & Consolidation of Comprehensive Preclinical Data Package
LEXEO Therapeutics recently announced it has licensed worldwide intellectual property rights and preclinical data from Adverum Biotechnologies to its….
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell & Gene Therapy Service Offerings for Global Customers
WuXi AppTec recently announced that it has completed the acquisition of OXGENE, a pioneering UK-based contract research and development organization that designs and develops scalable gene….
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology
Qualigen Therapeutics, Inc. recently announced it has entered into a Material Evaluation and Option Agreement with the University College London (UCL) to advance development of…
Enzo Announces its Molecular Test Detects Current COVID-19 Variants
Enzo Biochem, Inc. recently announced results of an analysis showing that tests processed on the company’s proprietary GENFLEX molecular diagnostic platform are successfully able to…
VYNE Therapeutics Announces Development Program for Combination Topical Gel
VYNE Therapeutics Inc. recently announced development plans for FMX114, a fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical…
Silo Pharma Enters Exclusive Option Agreement With the University of Maryland
Silo Pharma, Inc. recently announced it has executed an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known…
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study
NGM Biopharmaceuticals, Inc. recently announced it has dosed the first patient in an expansion of its ongoing Phase 1b proof-of-concept study of NGM120 in patients…
Aptamer Group Extends Collaboration With AstraZeneca to Explore Next-Generation Drug Delivery Approaches
Aptamer Group, the developer of Optimer reagents and therapeutics, recently announced the extension of its current agreement with AstraZeneca, a global biopharmaceutical company. This agreement…
AMRI Joins Network of Approved Manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine
Albany Molecular Research, Inc. recently announced that the company has been chosen to support the development and manufacture of lipid excipients for the Pfizer-BioNTech COVID-19 vaccine.…
Vaccinex Announces Signing of Two Multi-Project Deals With Leading Pharmaceutical Companies
Vaccinex, Inc. recently announced the signing of multi-project deals with two undisclosed prominent pharmaceutical companies…..
Stevanato Group Launches Artificial Intelligence Platform
Stevanato Group has recently launched an Artificial Intelligence platform, based on Deep Learning (DL) models, that leverages the benefits of….
